NASDAQ: GDTCCytomed Therapeutics Ltd Stock
$1.11-0.04 (-3.48%)
Updated Jun 16, 2026
GDTC Price
$1.11
Fair Value Price
N/A
Market Cap
$13.13M
52 Week Low
$0.68
52 Week High
$3.68
P/E
-4.17x
P/B
2.57x
P/S
61.35x
PEG
N/A
Dividend Yield
N/A
Revenue
$253.43k
Earnings
-$3.11M
Gross Margin
100%
Operating Margin
-1,220.63%
Profit Margin
-1,227.1%
Debt to Equity
0.17
Operating Cash Flow
-$3M
Beta
0.53
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
GDTC Overview
CytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical development phase, founded in 2018 and based in Singapore. The firm specializes in creating advanced cellular immunotherapies aimed at combating various human malignancies. Its primary investigational product, CTM-N2D, involves cultivated gamma delta T cells that are engineered with a chimeric antigen receptor (CAR) specifically targeting natural killer group 2D ligands, designed to boost their capacity to destroy cancer cells. Beyond its lead candidate, CytoMed is also advancing iPSC-gdNKT, which utilizes induced pluripotent stem cells (iPSCs) to generate a novel hybrid cell combining properties of both gamma delta T cells and natural killer cells. Additionally, the company is developing CTM-GDT, an immunotherapy consisting of expanded gamma delta T cells that leverages their innate, broad-spectrum recognition system to identify and address diverse cancer types.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine GDTC's potential to beat the market
- GDTC doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
GDTC
RankedUnranked of 462
RankedUnranked of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $226.88 | A | |
| $52.10 | A | |
| $16.22 | A |
Be the first to know about important GDTC news, forecast changes, insider trades & much more!
GDTC News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how GDTC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
GDTC is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
GDTC is good value based on its book value relative to its share price (2.57x), compared to the US Biotechnology industry average (4.86x)
P/B vs Industry Valuation
GDTC is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more GDTC due diligence checks available for Premium users.
Valuation
GDTC fair value
Fair Value of GDTC stock based on Discounted Cash Flow (DCF)
Price
$1.11
Fair Value
-$0.22
Undervalued by
615.65%
GDTC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
GDTC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-4.17x
Industry
16.03x
Market
13.25x
GDTC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.57x
Industry
4.86x
GDTC is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
GDTC's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
GDTC's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
GDTC's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$6.2M
Liabilities
$883.8k
Debt to equity
0.17
GDTC's short-term assets ($2.86M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GDTC's short-term assets ($2.86M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GDTC's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
GDTC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
GDTC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
GDTC vs Biotech Stocks
Cytomed Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.